Logo

J&J Unit Veridex Licenses OncoMethylome's Prostate Cancer Dx

Dec 15, 2006
NEW YORK (GenomeWeb News) — OncoMethylome Sciences today said it has licensed a prostate cancer test it is developing to Johnson & Johnson subsidiary Veridex.
 
OncoMethylome said it has completed the initial research phase of the urine-based test, and said Veridex will finish developing it and will have the rights to market the resulting product worldwide.
 
The company said that under the agreement it will receive an undisclosed milestone payment now and will be due royalties and sales milestones in the future.  
 
OncoMethylome said a urine-based test is better than tissue-based tests because 75 percent of the biopsies that are performed based on prostate-specific antigens return negative results, and because those tests sometimes miss cancer when it is present.
 
Financial terms of the deal were not released.

Breaking News
The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.